Intervention Review

Thiamine for Alzheimer's disease

  1. José-Luis Rodríguez1,*,
  2. Nawab Qizilbash2,
  3. Jess López-Arrieta3

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 23 APR 2001

Assessed as up-to-date: 5 MAY 2008

DOI: 10.1002/14651858.CD001498


How to Cite

Rodríguez JL, Qizilbash N, López-Arrieta J. Thiamine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD001498. DOI: 10.1002/14651858.CD001498.

Author Information

  1. 1

    University of Oxford, Department of Clinical Geratology, Oxford, UK

  2. 2

    SmithKline Beecham, Harlow, Essex, UK

  3. 3

    Hospital Universitario La Paz-Cantoblanco, Geriatric Department, Madrid, Spain

*José-Luis Rodríguez, Department of Clinical Geratology, University of Oxford, Radcliffe Infimary, Woodstock Road, Oxford, OX2 6HE, UK. jose.rodriguez@clinical-medicine.oxford.ac.uk.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 23 APR 2001

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. Laički sažetak

Background

Vitamin B1 (thiamine) deficiency plays an important role in Wernicke-Korsakoff syndrome. This is a form of brain damage occurring in long-term alcoholics who rely mainly on alcohol for nutrition. The acute syndrome (Wernicke's encephalopathy) is normally reversible. Progression to the profound amnestic syndrome (Korsakoff's psychosis) can be averted by a timely injection of a large dose of thiamine. There have been suggestions that thiamine may have a beneficial effect in Alzheimer's disease.

Objectives

The objective of this systematic review is to evaluate the efficacy of thiamine for people with Alzheimer's disease.

Search methods

The trials were identified from a last updated search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 12 February 2003 using the terms thiamin*, vitamin-B1, B1, "Vitmain B1". This Register is regularly updated with records from all major health care databases (MEDLINE, EMBASE, CINAHL, PsycINFO) and many trials databases.

In addition the reviewers searched bibliographies of published reviews and conference proceedings and contacted pharmaceutical companies and trial investigators to obtain additional data.

Selection criteria

All unconfounded, double-blind, randomized trials in which treatment with thiamine was administered for more than a day and compared with placebo in patients with dementia of the Alzheimer's type.

Data collection and analysis

Two reviewers extracted the data independently by and estimated the odds ratios (95% CI) or the average differences (95% CI).

Main results

Three studies were included. The two cross-over studies did not report results from the first phase. It was not possible to pool any results for a meta-analysis. Nolan 1991 reports results that show no evidence of an effect on MMSE at 3, 6, 9 and 12 months for thiamine compared with placebo for those who completed the trial. Meador 1993a noted that 3/8 on thiamine compared with 6/9 on placebo were worse as measured on the ADAS-Cog at 3 months compared with baseline, but the difference is not statistically significant.

Blass 1988 and Nolan 1991 reported that no significant side-effects were noted during the study, and Meador 1993a did not mention side-effects. Blass 1998 noted that 5/16 and Nolan 1991 that 5/15 did not complete the study, but neither mentioned the groups to which these people belonged.

Authors' conclusions

It is not possible to draw any conclusions from this review. The number of people included in the studies is less than 50 and the reported results are inadequate.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. Laički sažetak

Insufficient evidence of the efficacy of thiamine for people with Alzheimer's disease

Preclinical and laboratory studies show an effect of thiamine on the release and breakdown of acetylcholine. Some intellectual functions, including attention and memory, are influenced by neurons which release acetylcholine. Cholinergic function is impaired in Alzheimer's disease. It has therefore been hypothesized that thiamine may be beneficial in Alzheimer's disease. Biochemical abnormalities in thiamine-dependent enzymes have been found in the brains of patients with Alzheimer's disease. The three included randomized controlled trials totaled less than 50 participants and insufficient detail in the results did not allow combination of the data. Thus the review found no evidence of the efficacy of thiamine for people with Alzheimer's disease.

 

Laički sažetak

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. Laički sažetak

Nema dovoljno dokaza o učinkovitosti tiamina u ljudi s Alzheimerovom bolešću

Pretklinička i laboratorijska ispitivanja pokazuju učinak tiamina na otpuštanje i razgradnju acetilkolina. Pojedine su intelektualne funkcije, uključujući pozornost i pamćenje, pod utjecajem neurona koji otpuštaju acetilkolin. Kod Alzheimerove bolesti je oslabljena kolinergična funkcija. Stoga je postavljena hipoteza da tiamin može biti koristan kod Alzheimerove bolesti. U mozgu bolesnika s Alzheimerovom bolesti pronađene su biokemijske abnormalnosti enzima ovisnih o tiaminu. Tri uključena randomizirana kontrolirana istraživanja ukupno su imala manje od 50 sudionika a rezultati nisu prikazani dovoljno detaljno, što nije omogućilo kombiniranje podataka. Stoga ovaj Cochrane sustavni pregled nije pronašao dokaze o učinkovitosti tiamina u ljudi s Alzheimerovom bolešću.

Bilješke prijevoda

Cochrane Hrvatska
Prevela: Katarina Vučić
Ovaj sažetak preveden je u okviru volonterskog projekta prevođenja Cochrane sažetaka. Uključite se u projekt i pomozite nam u prevođenju brojnih preostalih Cochrane sažetaka koji su još uvijek dostupni samo na engleskom jeziku. Kontakt: cochrane_croatia@mefst.hr